Proceedings of Nigeria Centre for Disease Control/Nigeria Field Epidemiology and Laboratory Training Programme 2nd Annual Scientific Conference (Abuja, 2018)

Opening ceremony

Pattern of adverse drug reactions following anti-tuberculosis therapy in Nigeria: a four year review

Cite this: Pan African Medical Journal - Conference Proceedings. Mar 2018; 8(8): 21. doi:10.11604/pamj.cp.2018.8.21.603

Submitted: 15 Jan 18   Accepted: 30 Jan 18   Published: 22 Mar 18

Key words: Adverse drug reactions, tuberculosis, national pharmaco-vigilance center, Nigeria

© Oluwadamilola Abiodun-Adewusi et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Available online at: http://www.proceedings.panafrican-med-journal.com/conferences/2018/8/21/abstract

Corresponding author: Oluwadamilola Abiodun-Adewusi, Nigeria Field Epidemiology and Laboratory Training Programme, Asokoro, Abuja, Nigeria (damilnet@yahoo.com)

This abstract is published as part of the proceedings of Nigeria Centre for Disease Control/Nigeria Field Epidemiology and Laboratory Training Programme 2nd Annual Scientific Conference(NIGERIA, )

Pattern of adverse drug reactions following anti-tuberculosis therapy in Nigeria: a four year review

Oluwadamilola Abiodun-Adewusi1,&, Ibidolapo Ijarotimi1, Abisola Oladimeji1, Muhammad Balogun1, Adebobola Bashorun1, Mahmood Dalhat1, Saheed Gidado2, Patrick Nguku1, Adebola Olayinka1

 

1Nigeria Field Epidemiology and Laboratory Training Programme, Abuja, Nigeria, 2African Field Epidemiology Network (AFENET), Nigeria

 

 

&Corresponding author
Oluwadamilola Abiodun-Adewusi, Nigeria Field Epidemiology and Laboratory Training Programme, Asokoro, Abuja, Nigeria

 

 

Abstract

Introduction: combined anti-tuberculosis drugs are effective in the management of persons with tuberculosis (TB). These drug combinations have however been documented to increase the likelihood of adverse drug reactions (ADR), poor adherence and treatment failure among patients with TB. This study was therefore conducted to assess and describe the pattern of reported ADR to anti-TB therapy in Nigeria.

 

Methods: a retrospective analysis of the national pharmaco-vigilance data on reported ADR to TB therapy from 29 treatment centers/hospitals between June 2012 and June 2016 was done. Reported ADRs were classified using the WHO ICD 10. Frequencies and proportions were calculated, with test of associations done using chi square at α = 0.05.

 

Results: a total of 482 incidents of ADR to tuberculosis therapy were reported during the study period. Two hundred and fifty-seven (53.3%) were reported from the south-western zone of the country. Average age of persons with reported ADRs was 37.5 12.0 years, with a male to female ratio of 2:1. One hundred and twenty-six (26.0%) patients with reported ADRs were documented to have used both first and second-line anti-TB drugs concurrently, while 246 (51.0%) were secondary to the use of second-line anti-tuberculosis regimen only. Three-hundred and eight (64%) recovered fully, 48 (10%) recovered with disability while 10 (2%) died. Patients on second-line drugs were more likely to report psychiatric ADR (OR = 12.5, 95% CI = 3.7-40.1), while those on first-line regimen were more likely to report ototoxic ADR (OR = 7.9, 95% CI = 2.8 - 22.2). Compared to other regimen, patients on first-line regimen who experienced ADR were more likely to die (OR = 4.7, 95% CI = 1.0-21.2). Hepatic system-related ADRs also were more likely to result in death (OR = 37.1, 95% CI = 5.8-64.1), compared to other systems. Vestibulo-cochlear complications were more likely resolve with residual disabilities when compared with other complications (OR = 12.8, 95% CI = 6.5-25.1).

 

Conclusion: ADRs to anti-tuberculosis therapy remain a major cause of morbidity. Concurrent wrong use of first and second line anti-TB drugs must be stopped. All persons commencing anti-TB drugs should be well informed of possible ADRs and closely monitored. Mechanisms for immediate management of anti-TB ADRs should be instituted.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nigeria CDC/Nigeria Field Epidemiology and Laboratory Training Programme 2<sup>nd</sup> Annual Scientific Conference (Abuja)

To create a platform for epidemiologists and public health physicians to share their scientific works, NCDC/NFELTP organized the 2nd annual scientific conference with the theme "strengthening one health through field epidemiology training" at Transcorp Hilton Hotel, Abuja, Nigeria from July 5-7, 2017. The objectives of the conference were to provide residents and graduates a forum to share findings from their field activities; provide training opportunity for trainees on scientific communication; provide an opportunity for epidemiological networking as well as create a forum to discuss pertinent public health issues. In attendance were dignitaries from the United States Centers for Disease Control and Prevention (CDC), USAID, WHO, Africa CDC, Ministries Departments and Agencies, University officials and other implementing partners. With the current rise in zoonotic diseases, the conference also featured a two-day pre-conference workshop on One Health which prioritized zoonotic infectious diseases in Nigeria using standardized prioritization methods. A second workshop focused on antimicrobial resistance. There were 38 oral presentations, 60 poster presentations and 2 plenary sessions. The presentations covered various sub-themes ranging from outbreak investigations, case management, health system strengthening, vaccine preventable diseases, communicable diseases and surveillance. The conference featured a National Night and climaxed with awards to outstanding presenters.

Country: NIGERIA

Dates: 05 Jul 17 - 07 Jul 17

Venue: Transcorp Hilton Hotel

Organizers: Nigeria Centre for Disease Control / Nigeria Field Epidemiology and Laboratory Training Programme

Secretariat: gchinyere@afenet.net

Contact person: Dr Patrick Nguku (pnguku@afenet.net)